Form 4: DENTSPLY SIRONA Executive Receives Equity Awards

DENTSPLY SIRONA's SVP, Chief Supply Chain Officer, Robert Anthony Johnson, was granted Restricted Stock Units and stock options.

Summary

• Robert Anthony Johnson, SVP, Chief Supply Chain Officer of DENTSPLY SIRONA Inc. (XRAY), reported the acquisition of equity awards.
• The awards include 44,643 Restricted Stock Units (RSUs) and 202,700 stock options.
• The RSUs vest in annual one-third increments over a three-year period, concluding on March 4, 2029.
• The stock options also vest in annual one-third increments over a three-year period, ending March 4, 2029.
• The exercise price for the stock options is $14.78, which is stated to be 110% of the closing price of the Issuer's common stock as of the grant date.
• Following these transactions, Johnson beneficially owns 161,819.146 shares of Common Stock directly and 202,700 derivative stock options directly.
• The stock options have an expiration date of March 4, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents a routine executive compensation grant, aligning management incentives with shareholder interests, which is generally a positive for corporate governance and executive retention.

Positives

• The equity awards align the executive's interests with those of shareholders, promoting long-term value creation.
• The grant of RSUs and stock options serves as a retention mechanism for a key executive.

Future Outlook

The equity awards are structured with a three-year vesting period, indicating a long-term incentive for the executive to contribute to the company's performance through March 2029. The stock options have an extended expiration date until March 2036, providing a long window for potential value realization.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units and stock options is a standard practice in executive compensation across various industries, particularly in healthcare and medical device sectors like DENTSPLY SIRONA. This approach aims to incentivize long-term performance and align executive interests with shareholder value, a common trend in corporate governance.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry frequently include a mix of base salary, annual bonuses, and long-term equity incentives such as RSUs and stock options, similar to DENTSPLY SIRONA's approach.
• The three-year vesting schedule for equity awards is a common industry standard, observed in companies like Zimmer Biomet Holdings (ZBH) and Stryker Corporation (SYK), designed to promote executive retention and sustained performance.
• The use of an exercise price for stock options set at a premium (110% of the grant date closing price) is less common than at-the-money options but can be used to further incentivize significant stock price appreciation, a practice sometimes seen in high-growth or turnaround situations.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the executive's long-term financial interests with shareholder value creation, potentially leading to improved company performance.
• Employees: While not directly impacting all employees, executive compensation structures can influence overall company culture and incentive programs.

Next Steps

• The Restricted Stock Units and stock options will vest in one-third annual increments over the next three years, with full vesting by March 4, 2029.
• The stock options will become exercisable according to their vesting schedule and will expire on March 4, 2036.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Executive Compensation, Corporate Governance